Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
Department of Neurosciences, Medical University of South Carolina, Charleston, South Carolina.
J Am Coll Cardiol. 2014 Apr 29;63(16):1626-33. doi: 10.1016/j.jacc.2013.12.042. Epub 2014 Feb 26.
In a nonclinical trial setting, we sought to determine the proportion of individuals with coronary artery disease (CAD) with optimal risk factor levels based on the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation) trial.
In the COURAGE trial, the addition of percutaneous coronary intervention (PCI) to optimal medical therapy did not reduce the risk of death or myocardial infarction in stable CAD patients but resulted in more revascularization procedures.
The REGARDS (REasons for Geographic And Racial Differences in Stroke) study is a national prospective cohort study of 30,239 African-American and white community-dwelling individuals older than 45 years of age who enrolled in 2003 through 2007. We calculated the proportion of 3,167 participants with self-reported CAD meeting 7 risk factor goals based on the COURAGE trial: 1) aspirin use; 2) systolic blood pressure <130 mm Hg and diastolic blood pressure <85 mm Hg (<80 mm Hg if diabetic); 3) low-density lipoprotein cholesterol <85 mg/dl, high-density lipoprotein cholesterol >40 mg/dl, and triglycerides <150 mg/dl; 4) fasting glucose <126 mg/dl; 5) nonsmoking status; 6) body mass index <25 kg/m(2); and 7) exercise ≥4 days per week.
The mean age of participants was 69 ± 9 years; 33% were African American and 35% were female. Overall, the median number of goals met was 4. Less than one-fourth met ≥5 of the 7 goals, and 16% met all 3 goals for aspirin, blood pressure, and low-density lipoprotein cholesterol. Older age, white race, higher income, more education, and higher physical functioning were independently associated with meeting more goals.
There is substantial room for improvement in risk factor reduction among U.S. individuals with CAD.
在非临床试验环境中,我们试图根据 COURAGE(经皮冠状动脉介入治疗与强化药物治疗的临床结果评估)试验,确定冠状动脉疾病(CAD)患者中具有最佳风险因素水平的个体比例。
在 COURAGE 试验中,经皮冠状动脉介入治疗(PCI)加用最佳药物治疗并未降低稳定型 CAD 患者的死亡或心肌梗死风险,但导致更多的血运重建手术。
REasons for Geographic And Racial Differences in Stroke(REGARDS)研究是一项针对 30239 名年龄大于 45 岁的非洲裔美国人和白人社区居民的全国前瞻性队列研究,这些人于 2003 年至 2007 年期间参加了该研究。我们根据 COURAGE 试验计算了 3167 名自述患有 CAD 的参与者符合 7 个风险因素目标的比例:1)阿司匹林使用;2)收缩压<130mmHg 和舒张压<85mmHg(糖尿病患者<80mmHg);3)低密度脂蛋白胆固醇<85mg/dl,高密度脂蛋白胆固醇>40mg/dl,甘油三酯<150mg/dl;4)空腹血糖<126mg/dl;5)非吸烟状态;6)体质指数<25kg/m²;7)每周运动≥4 天。
参与者的平均年龄为 69±9 岁;33%为非裔美国人,35%为女性。总体而言,中位数达到的目标数为 4 个。不到四分之一的人达到了 7 个目标中的≥5 个,16%的人达到了阿司匹林、血压和低密度脂蛋白胆固醇的 3 个目标。年龄较大、白种人、较高的收入、较高的教育程度和较高的身体机能与达到更多目标独立相关。
美国 CAD 患者的风险因素降低仍有很大的改进空间。